Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management

被引：6

作者：

Jazayeri, Seyed Behzad ^{[1
]}

Srivastava, Abhishek ^{[2
]}

Shore, Neal ^{[2
]}

机构：

[1] Univ Florida, Dept Urol, Jacksonville, FL USA

[2] Genesis Care, Myrtle Beach, SC 29579 USA

来源：

CURRENT OPINION IN UROLOGY | 2022年 / 32卷 / 03期

关键词：

abiraterone; apalutamide; darolutamide; enzalutamide; prostate cancer; ACETATE PLUS PREDNISONE; RANDOMIZED PHASE-II; ABIRATERONE ACETATE; DOUBLE-BLIND; SURVIVAL ANALYSIS; ENZALUTAMIDE; TRIAL; MEN; APALUTAMIDE;

D O I：

10.1097/MOU.0000000000000984

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review We review the published literature on the indications of second-generation androgen receptor inhibitors, Poly(ADP-Ribose) Polymerase (PARP) inhibitors, combination therapies, and their evolution throughout the advanced prostate cancer continuum. Recent findings Enzalutamide trials have published data supporting its use in metastatic hormone-sensitive prostate cancer (mHSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC). Apalutamide trials have supported its indication for mHSPC and nmCRPC. Darolutamide trials currently support its use for nmCRPC. Abiraterone trials have supported its use in mCRPC and mHSPC. Olaparib and rucaparib have shown clinical benefit in heavily pretreated patients with mCRPC and DNA repair mutation genes. Phase 3 trials and peer-reviewed literature demonstrate that enzalutamide, apalutamide, and darolutamide prolong overall survival (OS) in men with nmCRPC. Abiraterone, enzalutamide, and apalutamide improve OS in men with mHSPC. Abiraterone and enzalutamide have data supporting improvement in OS in men with mCRPC

引用

页码：283 / 291

页数：9

共 48 条

[21] Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [J].

Fizazi, Karim ;

Scher, Howard I. ;

Molina, Arturo ;

Logothetis, Christopher J. ;

Chi, Kim N. ;

Jones, Robert J. ;

Staffurth, John N. ;

North, Scott ;

Vogelzang, Nicholas J. ;

Saad, Fred ;

Mainwaring, Paul ;

Harland, Stephen ;

Goodman, Oscar B., Jr. ;

Sternberg, Cora N. ;

Li, Jin Hui ;

Kheoh, Thian ;

Haqq, Christopher M. ;

de Bono, Johann S. .

LANCET ONCOLOGY, 2012, 13 (10) :983-992

[22] A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design [J].

Freedland, Stephen J. ;

De Giorgi, Ugo ;

Gleave, Martin ;

Rosbrook, Brad ;

Shen, Qi ;

Sugg, Jennifer ;

Haas, Gabriel P. ;

Shore, Neal D. .

BMJ OPEN, 2021, 11 (08)

[23] Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer [J].

Halabi, Susan ;

Jiang, Shan ;

Terasawa, Emi ;

Garcia-Horton, Viviana ;

Ayyagari, Rajeev ;

Waldeck, A. Reginald ;

Shore, Neal .

JOURNAL OF UROLOGY, 2021, 206 (02) :298-307

[24] Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer [J].

Hoyle, Alex P. ;

Ali, Adnan ;

James, Nicholas D. ;

Cook, Adrian ;

Parker, Christopher C. ;

de Bono, Johann S. ;

Attard, Gerhardt ;

Chowdhury, Simon ;

Cross, William R. ;

Dearnaley, David P. ;

Brawley, Christopher D. ;

Gilson, Clare ;

Ingleby, Fiona ;

Gillessen, Silke ;

Aebersold, Daniel M. ;

Jones, Rob J. ;

Matheson, David ;

Millman, Robin ;

Mason, Malcolm D. ;

Ritchie, Alastair W. S. ;

Russell, Martin ;

Douis, Hassan ;

Parmar, Mahesh K. B. ;

Sydes, Matthew R. ;

Clarke, Noel W. .

EUROPEAN UROLOGY, 2019, 76 (06) :719-728

[25] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study [J].

Iguchi, Taro ;

Kimura, Go ;

Fukasawa, Satoshi ;

Suzuki, Hiroyoshi ;

Uemura, Hiroji ;

Nishimura, Kazuo ;

Matsumoto, Hiroaki ;

Yokomizo, Akira ;

Armstrong, Andrew J. ;

Rosbrook, Brad ;

Sugg, Jennifer ;

Baron, Benoit ;

Chen, Lucy ;

Kunieda, Futoshi ;

Stenzl, Arnulf .

INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) :765-773

[26] Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study) [J].

Iguchi, Taro ;

Tamada, Satoshi ;

Kato, Minoru ;

Yasuda, Sayaka ;

Yamasaki, Takeshi ;

Nakatani, Tatsuya .

BMC CANCER, 2019, 19 (1)

[27] Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].

James, N. D. ;

de Bono, J. S. ;

Spears, M. R. ;

Clarke, N. W. ;

Mason, M. D. ;

Dearnaley, D. P. ;

Ritchie, A. W. S. ;

Amos, C. L. ;

Gilson, C. ;

Jones, R. J. ;

Matheson, D. ;

Miliman, R. ;

Attard, G. ;

Chowdhury, S. ;

Cross, W. R. ;

Gillessen, S. ;

Parker, C. C. ;

Russell, J. M. ;

Berthold, D. R. ;

Brawley, C. ;

Adab, F. ;

Aung, S. ;

Birtle, A. J. ;

Bowen, J. ;

Brock, S. ;

Chakraborti, P. ;

Ferguson, C. ;

Gale, J. ;

Gray, E. ;

Hingorani, M. ;

Hoskin, P. J. ;

Lester, J. F. ;

Malik, Z. I. ;

McKinna, F. ;

McPhail, N. ;

Money-Kyrle, J. ;

O'Sullivan, J. ;

Parikh, O. ;

Protheroe, A. ;

Robinson, A. ;

Srihari, N. N. ;

Thomas, C. ;

Wagstaff, J. ;

Wylie, J. ;

Zarkar, A. ;

Parmar, M. K. B. ;

Sydes, M. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351

[28] Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial [J].

Khalaf, Daniel J. ;

Annala, Matti ;

Taavitsainen, Sinja ;

Finch, Daygen L. ;

Oja, Conrad ;

Vergidis, Joanna ;

Zulfiqar, Muhammad ;

Sunderland, Katherine ;

Azad, Arun A. ;

Kollmannsberger, Christian K. ;

Eigl, Bernhard J. ;

Noonan, Krista ;

Wadhwa, Deepa ;

Attwell, Andrew ;

Keith, Bruce ;

Ellard, Susan L. ;

Le, Lyly ;

Gleave, Martin E. ;

Wyatt, Alexander W. ;

Chi, Kim N. .

LANCET ONCOLOGY, 2019, 20 (12) :1730-1739

[29] Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis [J].

Kumar, Jatinder ;

Jazayeri, Seyed Behzad ;

Gautam, Shiva ;

Norez, Daniel ;

Alam, Muhammad Umar ;

Tanneru, Karthik ;

Bazargani, Soroush ;

Costa, Joseph ;

Bandyk, Mark ;

Ganapathi, Hariharan Palayapalayam ;

Koochekpour, Shahriar ;

Balaji, K. C. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (11) :826-834

[30] Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? [J].

Kwon, Daniel H. ;

Booth, Christopher M. ;

Prasad, Vinay .

EUROPEAN UROLOGY, 2021, 79 (06) :710-712

← 1 2 3 4 5 →